CC
PSTX

Corton Capital’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Corton Capital’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-21,859
Closed -$67.3K – 522
2023
Q1 		$67.3K Buy
+21,859
New +$131K 0.05% 305
2022
Q3 		– Sell
-14,978
Closed -$39K – 389
2022
Q2 		$39K Sell
14,978
-43,049
-74% -$120K 0.04% 318
2022
Q1 		$260K Buy
+58,027
New +$262K 0.11% 276

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Corton Capital's PSTX Position: Q2 2023 in Review

Corton Capital sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q2 2023, closing a stake of 21,859 shares — an estimated $67.3K sold.

Corton Capital first reported a position in PSTX in Q1 2022 and held it in 3 quarters. The position peaked at $260K in Q1 2022. 94 funds tracked by Wall St. Rank hold PSTX as of Q2 2023.

  • Corton Capital reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Corton Capital sold 21,859 Poseida Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $67.3K.
  • Corton Capital first reported a position in Poseida Therapeutics, Inc. Common Stock in Q1 2022 and held it in 3 quarters.
  • Corton Capital's Poseida Therapeutics, Inc. Common Stock position peaked at $260K in Q1 2022.
  • 94 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Corton Capital's 13F filing for Q2 2023, filed 14 Aug 2023.